These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22107877)

  • 21. Use of naltrexone in treating opioid use disorder in pregnancy.
    Towers CV; Katz E; Weitz B; Visconti K
    Am J Obstet Gynecol; 2020 Jan; 222(1):83.e1-83.e8. PubMed ID: 31376396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
    Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
    Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of ultrarapid opiate detoxification combined with naltrexone maintenance and counseling.
    Rabinowitz J; Cohen H; Kotler M
    Psychiatr Serv; 1998 Jun; 49(6):831-3. PubMed ID: 9634168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Naltrexone plus benzodiazepine aids abstinence in opioid-dependent patients.
    Stella L; D'Ambra C; Mazzeo F; Capuano A; Del Franco F; Avolio A; Ambrosino F
    Life Sci; 2005 Oct; 77(21):2717-22. PubMed ID: 15979652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade?
    Sullivan MA; Bisaga A; Mariani JJ; Glass A; Levin FR; Comer SD; Nunes EV
    Drug Alcohol Depend; 2013 Nov; 133(1):80-5. PubMed ID: 23827259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence.
    Bisaga A; Sullivan MA; Glass A; Mishlen K; Carpenter KM; Mariani JJ; Levin FR; Nunes EV
    J Subst Abuse Treat; 2014; 46(5):546-52. PubMed ID: 24560438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Naltrexone in the treatment of opioid-dependent pregnant women: the case for a considered and measured approach to research.
    Jones HE; Chisolm MS; Jansson LM; Terplan M
    Addiction; 2013 Feb; 108(2):233-47. PubMed ID: 22471668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual dilemma-should naltrexone be used in the treatment of opioid-dependent pregnant women?
    Stitzer ML
    Addiction; 2013 Feb; 108(2):249-50. PubMed ID: 23331877
    [No Abstract]   [Full Text] [Related]  

  • 29. Gender differences in treatment and clinical characteristics among patients receiving extended release naltrexone.
    Herbeck DM; Jeter KE; Cousins SJ; Abdelmaksoud R; Crèvecoeur-MacPhail D
    J Addict Dis; 2016; 35(4):305-314. PubMed ID: 27192330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Injection Butorphanol dependence: A case report.
    Shah B; Gupta R; Sarkar S; Balhara YPS
    Asian J Psychiatr; 2018 Jun; 35():45-46. PubMed ID: 29778749
    [No Abstract]   [Full Text] [Related]  

  • 31. Maintenance medication for opiate addiction: the foundation of recovery.
    Bart G
    J Addict Dis; 2012; 31(3):207-25. PubMed ID: 22873183
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcome and six month follow up of patients after Ultra Rapid Opiate Detoxification (UROD).
    Albanese AP; Gevirtz C; Oppenheim B; Field JM; Abels I; Eustace JC
    J Addict Dis; 2000; 19(2):11-28. PubMed ID: 10809517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Naltrexone implant treatment for buprenorphine dependence--Mauritian case series.
    Jhugroo A; Ellayah D; Norman A; Hulse G
    J Psychopharmacol; 2014 Aug; 28(8):800-3. PubMed ID: 24695742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Naltrexone in the treatment of opioid dependence.
    George S; Ekhtiari H
    Br J Hosp Med (Lond); 2010 Oct; 71(10):568-70. PubMed ID: 21085073
    [No Abstract]   [Full Text] [Related]  

  • 35. [Detoxication in opiate addiction and prevention of recurrence: administration of naltrexone and cognitive behavior therapy].
    Roozen HG; Deden AL; Kerkhof AJ; Vorsteveld JP; van den Brink W
    Ned Tijdschr Geneeskd; 1997 Dec; 141(49):2377-80. PubMed ID: 9554156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Opioid antagonists for pharmacological treatment of alcohol dependence - a critical review.
    Soyka M; Rösner S
    Curr Drug Abuse Rev; 2008 Nov; 1(3):280-91. PubMed ID: 19630726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal.
    Mannelli P; Peindl K; Wu LT; Patkar AA; Gorelick DA
    Am J Drug Alcohol Abuse; 2012 May; 38(3):200-5. PubMed ID: 22233189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Alcohol consumption in opioid-dependence patients in treatment with naltrexone].
    Ochoa Mangado E; Arias Horcajadas F
    Actas Esp Psiquiatr; 2000; 28(4):239-49. PubMed ID: 11116795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort.
    Morgan JR; Schackman BR; Weinstein ZM; Walley AY; Linas BP
    Drug Alcohol Depend; 2019 Jul; 200():34-39. PubMed ID: 31082666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Naltrexone in the treatment of opioid-dependent pregnant women: common ground.
    Jones HE; Chisolm MS; Jansson LM; Terplan M
    Addiction; 2013 Feb; 108(2):255-6. PubMed ID: 23331881
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.